Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access July 8, 2014

Multiple endocrine neoplasia type 1: a case report and review of the literature

Audrius Šileikis, Edvinas Kildušis, Ramūnas Janavičius and Kęstutis Strupas
From the journal Open Medicine

Abstract

Multiple endocrine neoplasia syndrome, type 1 (MEN1) is an underdiagnosed autosomal dominant inherited cancer predisposition syndrome with inter- and intrafamilial variability without a known genotype-phenotype correlation. Disease is caused by mutations in the MEN1 gene located on chromosome 11, but other genes (CDKN1B, AIP) and mechanisms might be involved too. We performed retrospective case series study of MEN1 syndrome patient and his family and present our experience of management of genetically confirmed 9 MEN1 syndrome large family members from Lithuania with novel MEN1 gene mutation (MEN1 exon 6 — c. 879delT (p.Pro293Profs*76)) and delineate its clinical phenotype. At present the diagnosis of MEN1 syndrome must be established by direct mutation testing. MEN1 syndrome patients, their relatives and patients suspected of MEN1 are eligible for mutation testing. Patients with MEN1 have a shorter life expectancy than the general population. MEN1 patients and mutation carriers should be subjected to periodic screening in order to detect manifestations in an early stage. Early genetic diagnosis and subsequent periodic screening is associated with less morbidity and mortality at follow-up. Our study confirmed the absence of genotype-phenotype correlation and showed high intrafamilial clinical expression variability of the MEN1 syndrome.

[1] Pieterman C.R., Vriens M.R., Dreijerink K.M., van der Luijt R.B., Valk G.D., Care for patients with multiple endocrine neoplasia type 1: the current evidence base, Fam Cancer, 2011, 10, 157–171 http://dx.doi.org/10.1007/s10689-010-9398-610.1007/s10689-010-9398-6Search in Google Scholar

[2] Arnold A., Drezner M.K., Raby B.A., Mulder J.E., Multiple endocrine neoplasia type 1: Definition and genetics, 2012, http://www.uptodate.com/contents/multiple-endocrine-neoplasia-type-1-definitionand-genetics Search in Google Scholar

[3] Erdheim J., Zur normalen und pathologischen Histologie der Glandula Thyreoidea, Parathyreoidea und Hypophysis, Beitr Pathol Anat, 1903, 33, 158–263 Search in Google Scholar

[4] Underdahl L.O., Woolner L.B., Black B.M., Multiple endocrine adenomas; report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved, J Clin Endocrinol Metab, 1953, 13, 20–47 http://dx.doi.org/10.1210/jcem-13-1-2010.1210/jcem-13-1-20Search in Google Scholar

[5] Wermer P., Genetic aspects of adenomatosis of endocrine glands, Am J Med Sci, 1954, 16, 363–371 http://dx.doi.org/10.1016/0002-9343(54)90353-810.1016/0002-9343(54)90353-8Search in Google Scholar

[6] Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., et al., Positional cloning of the gene for multiple endocrine neoplasia-type 1, Science, 1997, 276, 404–407 http://dx.doi.org/10.1126/science.276.5311.40410.1126/science.276.5311.404Search in Google Scholar PubMed

[7] Kouvaraki M.A., Lee J.E., Shapiro S.E., Gagel R.F., Sherman S.I., Sellin R.V., et al., Genotypephenotype analysis in multiple endocrine neoplasia type 1, Arch Surg, 2002, 137, 641–647 http://dx.doi.org/10.1001/archsurg.137.6.64110.1001/archsurg.137.6.641Search in Google Scholar PubMed

[8] Bassett J.H., Forbes S.A., Pannett A.A., Lloyd S.E., Christie P.T., Wooding C., et al., Characterization of mutations in patients with multiple endocrine neoplasia type 1, Am J Hum Genet, 1998, 62, 232–244 http://dx.doi.org/10.1086/30172910.1086/301729Search in Google Scholar PubMed PubMed Central

[9] Carty S.E., Helm A.K., Amico J.A., Clarke M.R., Foley T.P., Watson C.G., et al., The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1, Surgery, 1998, 124, 1106–13, discussion 1113–1114 http://dx.doi.org/10.1067/msy.1998.9310710.1067/msy.1998.93107Search in Google Scholar PubMed

[10] Trump D., Farren B., Wooding C., Pang J.T., Besser G.M., Buchanan K.D., et al., Clinical studies of multiple endocrine neoplasia type 1 (MEN1), QJM, 1996, 89, 653–669 http://dx.doi.org/10.1093/qjmed/89.9.65310.1093/qjmed/89.9.653Search in Google Scholar PubMed

[11] Dean P.G., van Heerden J.A., Farley D.R., Thompson G.B., Grant C.S., Harmsen W.S., et al., Are patients with multiple endocrine neoplasia type I prone to premature death?, World J Surg, 2000, 24, 1437–1441 http://dx.doi.org/10.1007/s00268001023710.1007/s002680010237Search in Google Scholar PubMed

[12] Doherty G.M., Olson J.A., Frisella M.M., Lairmore T.C., Wells S.A. Jr., Norton J.A., Lethality of multiple endocrine neoplasia type I, World J Surg, 1998, 22, 581–6, discussion 586–587 http://dx.doi.org/10.1007/s00268990043810.1007/s002689900438Search in Google Scholar PubMed

[13] Geerdink E.A., Van der Luijt R.B., Lips C.J., Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening?, Eur J Endocrinol, 2003, 149, 577–582 http://dx.doi.org/10.1530/eje.0.149057710.1530/eje.0.1490577Search in Google Scholar

[14] Goudet P., Murat A., Binquet C., Cardot-Bauters C., Costa A., Ruszniewski P., et al., Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients, World J Surg, 2010, 34, 249–255 http://dx.doi.org/10.1007/s00268-009-0290-110.1007/s00268-009-0290-1Search in Google Scholar

[15] Taguchi R., Yamada M., Horiguchi K., Tomaru T., Ozawa A., Shibusawa N., et al., Haploinsufficient and predominant expression of multiple endocrine neoplasia type 1 (MEN1)-related genes, MLL, p27Kip1 and p18Ink4C in endocrine organs, Biochem Biophys Res Commun, 2011, 415, 378–383 http://dx.doi.org/10.1016/j.bbrc.2011.10.07710.1016/j.bbrc.2011.10.077Search in Google Scholar

[16] Arnold A., Drezner M.K., Mulder J.E., Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis, 2012, http://www.uptodate.com/contents/multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis Search in Google Scholar

[17] Guarnieri V., Baorda F., Corbetta S., Battista C., Spada A., D’Agruma L., et al., Identification and functional analysis of novel variants of CDKN1B (encoding p27Kip1) in sporadic parathyroid tumors from an Italian cohort, 113th International Workshop on Multiple Endocrine Neoplasia, Final Program & Abstract Book, 2012, 58 Search in Google Scholar

[18] Circelli L., Ramundo V., Marciello F., Del Prete M., Marotta V., Carratù A.C., et al., CDKN1B V109G polymorphism as a new putative prognostic factor in multiple endocrine neoplasia type 1 (MEN 1) patients, 113th International Workshop on Multiple Endocrine Neoplasia, Final Program & Abstract Book, 2012, 58–59 Search in Google Scholar

[19] Modlin I.M., Gustafsson B.I., Moss S.F., Pavel M., Tsolakis A.V., Kidd M., Chromogranin A — biological function and clinical utility in neuro endocrine tumor disease, Ann Surg Oncol, 2010, 17, 2427–2443 http://dx.doi.org/10.1245/s10434-010-1006-310.1245/s10434-010-1006-3Search in Google Scholar

[20] Nikou G.C., Marinou K., Thomakos P., Papageorgiou D., Sanzanidis V., Nikolaou P., Kosmidis C., Moulakakis A., Mallas E, Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours, Pancreatology, 2008, 8, 510–519 http://dx.doi.org/10.1159/00015200010.1159/000152000Search in Google Scholar

[21] O’Toole D., Grossman A., Gross D., Delle Fave G., Barkmanova J., O’Connor J., Pape U.F., Plöckinger U., Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers, Neuroendocrinology, 2009, 90, 194–120 http://dx.doi.org/10.1159/00022594810.1159/000225948Search in Google Scholar

[22] Sciortino G., Vitale G., Manfredi G., Guizzardi F., Persani L., Different phenotypes of multiple endocrine neoplasia type 1 (MEN1): a case report of an Italian family, 13th International Workshop on Multiple Endocrine Neoplasia, Final Program & Abstract Book, 2012, 62–63 Search in Google Scholar

[23] Weisbrod A.B., Nilubol N., Weinstein L.S., Simonds W.F., Libutti S.K., Jensen R.T., et al., Association of Type-O Blood with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1, 13th International Workshop on Multiple Endocrine Neoplasia, Final Program & Abstract Book, 2012, 50 10.1210/jc.2012-2781Search in Google Scholar

[24] Faggiano A., Tavares L.B., Tauchmanova L., Milone F., Mansueto G., Ramundo V., De Caro M.L., Lombardi G., De Rosa G., Colao A., Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients, Clin Endocrinol (Oxf), 2008, 69, 756–762 http://dx.doi.org/10.1111/j.1365-2265.2008.03301.x10.1111/j.1365-2265.2008.03301.xSearch in Google Scholar

[25] Burgess J.R., Greenaway T.M., Parameswaran V., Shepherd J.J., Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1), Implications for an integrated model of MEN-1 tumorigenesis, Cancer, 1999, 86, 2154–2159 http://dx.doi.org/10.1002/(SICI)1097-0142(19991115)86:10<2154::AID-CNCR39>3.0.CO;2-W10.1002/(SICI)1097-0142(19991115)86:10<2154::AID-CNCR39>3.0.CO;2-WSearch in Google Scholar

[26] Ramage J.K., Ahmed A., Ardill J., Bax N., Breen D.J., Caplin M.E., Corrie P., Davar J., Davies A.H., Lewington V., Meyer T., Newell-Price J., Poston G., Reed N., Rockall A., Steward W., Thakker R.V., Toubanakis C., Valle J., Verbeke C., Grossman A.B., Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs), Gut, 2012, 61, 6–32 http://dx.doi.org/10.1136/gutjnl-2011-30083110.1136/gutjnl-2011-300831Search in Google Scholar

[27] Arnold A., Snyder P.J., Drezner M.K., Mulder J.E., et al., Multiple endocrine neoplasia type 1: Treatment, 2012, http://www.uptodate.com/contents/multiple-endocrine-neoplasia-type-1-treatment Search in Google Scholar

[28] Lopez C.L., Waldmann J., Fendrich V., Langer P., Kann P.H., Bartsch D.K., et al., Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1, Langenbecks Arch Surg, 2011, 396, 1187–1196 http://dx.doi.org/10.1007/s00423-011-0828-110.1007/s00423-011-0828-1Search in Google Scholar PubMed

[29] Huang L.C., Poultsides G.A., Norton J.A., Surgical Management of Neuroendocrine Tumors of the Gastrointestinal Tract, Oncology (Williston Park), 2011, 25, 794–803 Search in Google Scholar

Published Online: 2014-7-8
Published in Print: 2014-6-1

© 2014 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Scroll Up Arrow